Trial Profile
A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Cluster headache; Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 30 Sep 2016 Results presented at the 16th World Congress on Pain
- 12 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov